Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Determination of Rates and Severity of cytokine release syndrome/Neurologic toxicities and Efficacy and Utility of toxicity management strategies of blinatumomab therapy

Next Previous
Trial Profile

Determination of Rates and Severity of cytokine release syndrome/Neurologic toxicities and Efficacy and Utility of toxicity management strategies of blinatumomab therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 06 Dec 2019 New trial record
  • 06 Nov 2019 Results assessing rates,severity of cytokine release syndrome and neurologic toxicities and efficacy of toxicity management strategies,released in 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top